ストックスクリーナーアプリを入手
4.46
4.70%
-0.22
Whitehawk Therapeutics Inc (WHWK) 最新ニュース
Whitehawk Therapeutics, Inc. (NASDAQ: WHWK) Stock Price, News & Analysis - Kalkine
Whitehawk Therapeutics (NASDAQ:WHWK) Rating Increased to Hold at Wall Street Zen - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
JonesTrading Maintains Whitehawk Therapeutics(WHWK.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Whitehawk Therapeutics (NASDAQ:WHWK) Announces Quarterly Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
Aadi Bioscience Inc (3350.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Form 8K Whitehawk Therapeutics Inc For: 6 August By Investing.com - Investing.com Nigeria
Whitehawk Therapeutics 2Q 2026: Revenue $0 Net loss $16.64M, EPS $(0.20) — 10-Q Summary - TradingView
Whitehawk Therapeutics reports Q2 2026 net loss $16.6M; cash $190.0M funds into 2H 2028 - TradingView
Whitehawk Therapeutics reports $16.6 million Q2 loss as trials advance - Quiver Quantitative
Whitehawk Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Whitehawk Therapeutics 2Q Loss/Shr 20c >WHWK - Moomoo
Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights - PR Newswire
Whitehawk Therapeutics (WHWK) Slips 1.7% as Shares Hover Between Support and ResistanceWave Extension - dars.gov.et
Akari Therapeutics Highlights WhiteHawk Collaboration and Dual-Payload ADC Strategy in CEO Corner Segment - quiverquant.com
Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation - Yahoo Finance
Stempoint Capital LP Sells 519,438 Shares of Whitehawk Therapeutics, Inc. $WHWK - MarketBeat
Whitehawk Therapeutics Inc (WHWK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
WHWK|WHWK|Price:3.940|Chg%:+0.090 - tradingkey.com
WHWK Stock Edges Up After Hours: Firm Boosts Pipeline Of Cancer Drugs On The Heels Of Capital Raise - Stocktwits
WHWK|WHWK|Price:3.710|Chg%:-0.120 - TradingKey
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Akari Therapeutics Collaborates with Whitehawk Therapeutics to Expand ADC Payload Platform Potential - Barchart.com
WHWK|Price:3.710|Chg%:-0.120 - TradingKey
Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity - GlobeNewswire
Akari and Whitehawk collaborate on ADC research - BioWorld News
Akari Therapeutics Announces Strategic Preclinical Research Collaboration with Whitehawk Therapeutics on Dual-Payload ADC Development - Quiver Quantitative
Akari and Whitehawk to Test Two ADC Payloads in Preclinical Studies - Stock Titan
Whitehawk Therapeutics(WHWK) Stock Options Chain | Quotes & News - Moomoo
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics - Yahoo Finance
How Low Will Whitehawk (WHWK) Go After -2.57% Sell-Off? 2026-07-20Sector Leader Stocks - po-news-eg.net
Whitehawk Therapeutics (WHWK) 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA summary - Quartr
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Sees Large Increase in Short Interest - MarketBeat
WHWK Initiated Coverage by Leerink Partners -- Rating Set to Out - GuruFocus
Price to book forward of Whitehawk Therapeutics, Inc. – HAM:3350 - TradingView
Leerink Partners Initiates Whitehawk Therapeutics(WHWK.US) With Buy Rating, Announces Target Price $9 - Moomoo
Whitehawk Therapeutics (NASDAQ:WHWK) Earns Outperform Rating from Analysts at Leerink Partners - MarketBeat
WHWK Q1 2026 Earnings: Narrower Loss Beats Estimates, Shares Gain on Cost ControlEarnings Cycle Outlook - dars.gov.et
Biocytogen and Whitehawk partner to develop ADCs - Yahoo Finance
Whitehawk Therapeutics (WHWK) Q4 2024 earnings summary - Quartr
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody Adc Development - marketscreener.com
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development - Business Upturn
Whitehawk Therapeutics (WHWK) Slips 4% as Stock Tests Key Support LevelsMid Cap Momentum - dars.gov.et
WHWKWhitehawk Therapeutics Inc Options - Finviz
Whitehawk Therapeutics (WHWK) Gains 6.1% as Biotech Sector Momentum BuildsVolatility Term Structure - dars.gov.et
Whitehawk Therapeutics, Inc.(NasdaqCM: WHWK) added to Russell 2000 Index - marketscreener.com
Whitehawk Therapeutics, Inc.(NasdaqCM: WHWK) added to Russell 2000 Value Benchmark - marketscreener.com
Whitehawk Therapeutics, Inc.(NasdaqCM:WHWK) added to Russell 3000E Value Benchmark - marketscreener.com
Price to sales forward of Whitehawk Therapeutics, Inc. – NASDAQ:WHWK - TradingView
Price to sales forward of Whitehawk Therapeutics, Inc. – FWB:3350 - TradingView
Enterprise value to revenue forward of Whitehawk Therapeutics, Inc. – NASDAQ:WHWK - TradingView
Enterprise value to revenue forward of Whitehawk Therapeutics, Inc. – FWB:3350 - TradingView
B. Riley Securities Initiates Whitehawk Therapeutics(WHWK.US) With Buy Rating, Announces Target Price $10 - Moomoo
Whitehawk Therapeutics, Inc. Actuals & Estimates (NASDAQ:WHWK) - TradingView
Whitehawk Therapeutics, Inc. Actuals & Estimates (DUS:3350) - TradingView
Price to earnings forward of Whitehawk Therapeutics, Inc. – NASDAQ:WHWK - TradingView
Enterprise value to EBITDA forward of Whitehawk Therapeutics, Inc. – NASDAQ:WHWK - TradingView
WHWK Initiated Coverage by B. Riley Securities -- Rating Set to Buy - GuruFocus
WHWK Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Whitehawk Therapeutics, Inc. – DUS:3350 - TradingView
B.Riley initiates Whitehawk Therapeutics stock rating at Buy on ADC portfolio - Investing.com Canada
Enterprise value to EBIT forward of Whitehawk Therapeutics, Inc. – NASDAQ:WHWK - TradingView
Price to book forward of Whitehawk Therapeutics, Inc. – DUS:3350 - TradingView
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):